Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FABP3
REST API REST API
Homo sapiens
FABP3 is differentially expressed in 211 experiments: 137 organism parts: heart, liver, ... (135 more);, 213 disease states: normal, melanoma, ... (211 more);, 70 cell types 204 cell lines 21 compound treatments and 63 other conditions.
Synonyms H-FABP, O-FABP, FABP11, MDGI
Orthologs Fabp3 (Mus musculus)   FABP3 (Gallus gallus)   FABPH_BOVIN (Bos taurus)   Fabp3 (Rattus norvegicus)   FABP3 (Canis familiaris)   fabp3 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term transporter activity, cytosol, fatty acid metabolic process, cytoplasm, negative regulation of cell proliferation, lipid binding, fatty acid binding, response to drug, binding, phosphatidylcholine biosynthetic process, sarcoplasm, long-chain fatty acid transport, response to fatty acid, long-chain fatty acid transporter activity, response to insulin stimulus, icosatetraenoic acid binding
InterPro Term Fatty_acid-bd, Lipocln_cytosolic_FA-bd_dom
UniProt Accession P05413
Search EB-eye ENSG00000121769
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-18005, E-GEOD-2450, E-GEOD-4717, E-MTAB-62, ... (26 experiments)

Factor Value U/D Experiments
MCF7
2
E-GEOD-5258, E-MTAB-37
SW480
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
UACC812
1
E-MTAB-37
SW1783
1
E-MTAB-37
primary pancreatic ductal adenocarcinoma
1
E-MEXP-2826
NA19140
1
E-GEOD-19480
198 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13987, ... (42 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
neutrophil
1
2
E-GEOD-3982, E-GEOD-995, E-GEOD-12662
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
multipotent adult progenitor cell
1
E-MEXP-466
CD34+ cell
1
E-MEXP-583
CD19+ B cell
1
1
E-MEXP-1600
64 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-2280, E-GEOD-22148, E-GEOD-16363, ... (43 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
207 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5824, E-GEOD-5099, E-MEXP-1958, E-MEXP-2590, ... (13 experiments)

Factor Value U/D Experiments
NaOH
1
1
E-MEXP-2590
SDF
1
1
E-GEOD-7307
placebo
1
E-MEXP-1335
glucose
1
E-MEXP-941
bacterial endotoxin
1
E-GEOD-3284
estradiol
1
E-GEOD-20081
15 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653

Factor Value U/D Experiments
24
1
1
E-GEOD-21653
29
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-TABM-147 ... (5 experiments)

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-20847, E-MTAB-108

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-GEOD-20504, E-GEOD-22278, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-MEXP-1956, E-TABM-26, ... (25 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-MTAB-197, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541

Vehicle
studied in E-GEOD-5258

Processing time: 0.303 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM